According to FIERCE Pharma, following the successive exits of Takeda, Pfizer, UCB, WuXi AppTec and other companies, another MNC — GSK — has announced that it will withdraw from the Biotechnology Innovation Organization (BIO) in 2025.A spokesperson for British pharmaceutical company GSK said in an emailed statement that after conducting its annual review of corporate memberships and industry association involvement, the company has chosen not to renew its BIO membership for 2025."The company representative added, 'We will continue to focus on creating a policy environment that prioritizes disease prevention, addresses health equity and access barriers, and encourages sustainable innovation.' At present, we believe resources can also be concentrated in other areas."The Biotechnology Innovation Organization (BIO) is the world's largest trade association representing biotechnology companies, founded in 1993 with the mission to advocate for and promote biotechnology innovation. Currently, companies such as AstraZeneca, Bayer, Eisai, Eli Lilly, GSK, and Amgen are on the association’s membership list. Meanwhile, executives from Roche, Novartis, Takeda, Regeneron, Merck, and Johnson & Johnson serve on the organization’s executive committee. The lobbying group was originally established to lobby the federal government to support industry development and protect member interests.However, since December last year, several large pharmaceutical companies have announced their withdrawal from BIO.Pfizer and UCB exited BIO in December 2023 and January 2024, respectively, while AbbVie severed ties with BIO in 2022.On March 13, 2024, WuXi AppTec withdrew due to BIO's support for the U.S. House of Representatives' confirmation of the Biosecure Act, which specifically targets five Chinese life sciences companies, including WuXi AppTec and WuXi Biologics.Takeda Pharmaceutical also decided not to renew its membership after the routine review in April 2024.The emergence of the "decoupling wave" is due to the decline in the lobbying influence exerted by the organization.In 2017, BIO spent over $9.3 million lobbying the federal government on issues such as drug imports, Medicare Part D, the 340B Drug Discount Program, and orphan drugs for treating rare diseases. From 2019 to 2022, expenditures further increased, with annual spending reaching $12-13 million.BIO's revenue mainly comes from membership fees and event charges such as the San Diego conference. According to BIO's latest financial report, in 2022, the aforementioned event charges accounted for nearly two-thirds of the non-profit organization's income.Despite relying on international members and events for revenue, BIO openly expressed support for the rising forces of deglobalization and patriotism in American politics during its annual meeting held in San Diego.As the Biden administration signed the Inflation Reduction Act (IRA) in August 2022, drug prices faced unprecedented challenges. BIO and PhRMA filed appeals successively, but even with substantial investments, they were unable to prevent government intervention in drug pricing.This has also directly led to the withdrawal of major pharmaceutical companies.GSK's Exit from Lobbying Groups Comes as Trump Poised to Return: Future of IRA Uncertain Amid Potential RollbacksAs for BIO, the organization "looks forward to working closely with Trump and his incoming administration." John Crowley, CEO of the Biotechnology Innovation Organization, stated in a declaration: "Strong leadership that respects and advances science and medicine, ensuring the United States and its allies continue to lead the world in biotechnology, is most beneficial for public health and national security."Source: PharmaResearch NetworkPharmaceutical ResearchReportSharing CampCollect and Share Mainstream Pharmaceutical Research Reports Across the Market
Only 0.8 yuan per day
EnjoyMore than 1900 articlesSelected Medical Research Reports
New additions in the next yearAdditional 500 Articles
